Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. May 7, 2013; 19(17): 2691-2696
Published online May 7, 2013. doi: 10.3748/wjg.v19.i17.2691
Published online May 7, 2013. doi: 10.3748/wjg.v19.i17.2691
Inclusion criteria |
Age ≥ 18 yr and ≤ 60 yr |
Positive HCV antibodies and detectable HCV RNA by PCR |
Positive liver biopsy for chronic hepatitis with F1 METAVIR score and elevated liver enzymes or F2/F3 METAVIR score |
Naïve to treatment with PEG-IFN and RIB |
Hepatitis B surface antigen negativity |
Normal complete blood count, normal thyroid function, prothrombin concentration ≥ 60%, normal bilirubin, α-fetoprotein < 100 (ng/mL) and antinuclear antibody titer < 1/160 |
Exclusion criteria |
Serious co-morbid conditions such as severe arterial hypertension, heart failure, significant coronary heart disease, poorly controlled diabetes (hemoglobin A1C > 8.5%), chronic obstructive pulmonary disease |
Major uncontrolled depressive illness |
Solid transplant organ (renal, heart, or lung) |
Untreated thyroid disease |
History of previous anti-HCV therapy |
Body mass index (BMI) > 35 kg/m² |
Known human immunodeficiency virus (HIV) coinfection |
Hypersensitivity to one of the two drugs (PEG-IFN, RIB) |
Concomitant liver disease other than hepatitis C (chronic hepatitis B, autoimmune hepatitis, alcoholic liver disease, hemochromatosis, α-1 antitrypsin deficiency, Wilson’s disease) |
Liver biopsy showing severe steatosis (> 66%) and steatohepatitis, decompensated cirrhosis, hepatocellular carcinoma or METAVIR score F4 |
- Citation: Abdel-Rahman M, El-Sayed M, El Raziky M, Elsharkawy A, El-Akel W, Ghoneim H, Khattab H, Esmat G. Coinfection with hepatitis C virus and schistosomiasis: Fibrosis and treatment response. World J Gastroenterol 2013; 19(17): 2691-2696
- URL: https://www.wjgnet.com/1007-9327/full/v19/i17/2691.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i17.2691